Majed Fawaz is the Vice President of CMC at atai Life Sciences AG. Dr. Fawaz has over 25 years of experience in drug development and has contributed to several marketed drugs: Abraxane®, Incivek®, Kalydeco®, Orkambi®, and Symdeko®. Prior to ATAI, Dr. Fawaz held several positions: SVP of CMC at Proteostasis Therapeutics, Senior Director of Formulation and Analytical Development at Axcella, Director of Materials Discovery and Characterization at Vertex Pharmaceuticals, and Analytical Senior Manager at Abraxis Biosciences.
Dr. Fawaz received his PhD. In Analytical Chemistry from the University Joseph Fourier in Grenoble, France where he held a position of Assistant Professor at the college of Pharmacy. He holds a Bachelor of Science in Pharmacy, a Master of Science in Chemical Pharmacology, and a Master of Science in Food Quality Control from the same university.